Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SHP2-IN-9 is a potent inhibitor (IC50 = 1.174 μM) specifically targeting the SHP2 protein, displaying improved penetration across the blood-brain barrier. It exhibits a remarkable 85-fold selectivity for SHP2 over SHP1. By inhibiting SHP2-mediated cell signal transduction and impairing cancer cell proliferation, SHP2-IN-9 effectively suppresses the growth of both cervix cancer tumors and glioblastoma in vivo [1].
Description | SHP2-IN-9 is a potent inhibitor (IC50 = 1.174 μM) specifically targeting the SHP2 protein, displaying improved penetration across the blood-brain barrier. It exhibits a remarkable 85-fold selectivity for SHP2 over SHP1. By inhibiting SHP2-mediated cell signal transduction and impairing cancer cell proliferation, SHP2-IN-9 effectively suppresses the growth of both cervix cancer tumors and glioblastoma in vivo [1]. |
In vitro | SHP2-IN-9 (compound 2) effectively disrupts SHP2-mediated cell signaling pathways in various cancers (cervix cancer, human pancreatic cancer, large cell lung cancer, and mouse glioma cell) by inhibiting Paxillin phosphorylation. This inhibition interferes with the PI3K/AKT pathway regulation and inhibits cell proliferation, leading to cell cycle arrest and early apoptosis induction [1]. |
Molecular Weight | 385.46 |
Formula | C20H20FN3O2S |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.